- info@novaerus.ie
- +353 (1) 255 1536
MMHCC implemented the NV200 and NV900 units in selected areas.
This study compares the total number of nosocomial respiratory infections and nosocomial C. difficile infections before and after implementation of the Novaerus technology.
A 24-month review was conducted to evaluate the results of implementation.
A Nurse Risk Manager Consultant visited the facility for two days to abstract information and review the data.
The periods selected for pre- and post-Novaerus review were June 2013 through February 2014 and June 2014 through February 2015. Comparison of like periods reduces the risk of skewed data related to seasonal variances.
In the period after implementation of the NV200 and NV900 units in selected areas, the total number of nosocomial respiratory infections at MMHCC decreased from 84 to 48, a 42.86% reduction.
The total number of nosocomial C. difficile infections decreased from 12 to 6, a 50.00% reduction.
About Us
Novaerus is on a mission to reduce indoor airborne pollutants that lead to infection, allergies, asthma, and odour.
The patented plasma NanoStrike technology used in Novaerus portable devices was invented in Ireland in 2006.
Novaerus Devices
Stay Connected to Novaerus
To keep up to date with all developments and for the latest research and scientifically proven results please follow us on LinkedIn, Facebook and Youtube.
